Literature DB >> 31813105

Diverse roles of arrest defective 1 in cancer development.

Prerna Chaudhary1, Eunyoung Ha1, Tam Thuy Lu Vo1, Ji Hae Seo2.   

Abstract

Arrest defective 1 is an acetyltransferase that acetylates N-terminal amino acid or internal lysine residues of its target proteins. By acetylating its target proteins, ARD1 plays roles in many cellular activities, including proliferation, differentiation, autophagy, and apoptosis. In recent years, a number of investigations have emerged reporting the dysregulated expression of ARD1 in different types of cancer, including lung, liver, pancreas, breast, prostate, and colon cancer. Furthermore, the expression level of ARD1 in cancer tissues has been correlated with the progression and metastasis of the cancer and the survival of cancer patients. Consequently, mechanistic studies have revealed that ARD1-mediated protein acetylation plays an important role in modulating several cellular events that are important for cancer development, such as cell cycle progression, cell death, and migration. On the basis of this evidence, targeting of ARD1 has been proposed as a promising avenue for the development of novel cancer therapeutics. This review summarizes the biological functions of ARD1 in different types of cancer and provides a deep insight into the biochemical activities of ARD1 during tumor progression.

Entities:  

Keywords:  ARD1; Acetylation; Acetyltransferase; Tumorigenesis

Mesh:

Substances:

Year:  2019        PMID: 31813105     DOI: 10.1007/s12272-019-01195-0

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  4 in total

1.  ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy.

Authors:  Seong-Jun Park; Sang Hoon Joo; Naeun Lee; Won-Jun Jang; Ji Hae Seo; Chul-Ho Jeong
Journal:  Arch Pharm Res       Date:  2021-11-10       Impact factor: 4.946

Review 2.  Lysine Acetyltransferases and Their Role in AR Signaling and Prostate Cancer.

Authors:  Bharti Jaiswal; Akanksha Agarwal; Ashish Gupta
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-17       Impact factor: 6.055

3.  Identification of NAA40 as a Potential Prognostic Marker for Aggressive Liver Cancer Subtypes.

Authors:  Costas Koufaris; Antonis Kirmizis
Journal:  Front Oncol       Date:  2021-06-02       Impact factor: 6.244

4.  Characterization of Lysine Acetyltransferase Activity of Recombinant Human ARD1/NAA10.

Authors:  Tam Thuy Lu Vo; Ji-Hyeon Park; Eun Ji Lee; Yen Thi Kim Nguyen; Byung Woo Han; Hien Thi Thu Nguyen; Kyo Cheol Mun; Eunyoung Ha; Taeg Kyu Kwon; Kyu-Won Kim; Chul-Ho Jeong; Ji Hae Seo
Journal:  Molecules       Date:  2020-01-29       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.